2024
MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE. Journal Of Urology 2024, 211: e241. DOI: 10.1097/01.ju.0001008640.01272.9d.06.Peer-Reviewed Original ResearchONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomesA0742 The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance
Contieri R, Tan W, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. A0742 The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance. European Urology 2024, 85: s1717. DOI: 10.1016/s0302-2838(24)01313-7.Peer-Reviewed Original Research
2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective studyOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalPD13-12 BLADDER SPARING TREATMENT IN PATIENTS WITH BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: AN ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES
Tan W, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Navai N, Dinney C, Kamat A. PD13-12 BLADDER SPARING TREATMENT IN PATIENTS WITH BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: AN ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES. Journal Of Urology 2023, 209: e410. DOI: 10.1097/ju.0000000000003260.12.Peer-Reviewed Original ResearchMP54-14 MENTAL HEALTH ILLNESS IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER. DOES BCG PLAY A ROLE?
Grajales V, Duan Z, Tan W, Contieri R, Zhao H, Giordano S, Williams S, Kamat A. MP54-14 MENTAL HEALTH ILLNESS IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER. DOES BCG PLAY A ROLE? Journal Of Urology 2023, 209: e759. DOI: 10.1097/ju.0000000000003307.14.Peer-Reviewed Original ResearchPD29-05 ASSOCIATION OF AGE WITH NON-MUSCLE INVASIVE BLADDER CANCER: A BIOLOGICAL BASIS FOR EPIDEMIOLOGICAL DISPARITIES?
Lobo N, Sood A, Duan Z, Tan W, Grajales V, Lindskrog S, Dyrskjøt L, Aarhus, Denmark, Zhao H, Giordano S, Williams S, Kamat A. PD29-05 ASSOCIATION OF AGE WITH NON-MUSCLE INVASIVE BLADDER CANCER: A BIOLOGICAL BASIS FOR EPIDEMIOLOGICAL DISPARITIES? Journal Of Urology 2023, 209: e826. DOI: 10.1097/ju.0000000000003315.05.Peer-Reviewed Original ResearchEvolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2022
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Tan W, Bello A, Alvarez C, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Goizueta F, Del Álamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, Mata J, Moreno J, Molina F, Semino M, Stemberger A, Escudero J, Redorta J, Tan W. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. Bladder Cancer 2022, 8: 379-393. PMID: 38994184, PMCID: PMC11181696, DOI: 10.3233/blc-220026.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerTransurethral resection of bladder tumorRecurrence-free survivalProgression-free survivalInvasive bladder cancerMitomycin CBCG-naiveBladder cancerAdverse eventsTreated with intravesical bacillus Calmette-GuerinTreatment of non-muscle invasive bladder cancerIntravesical bacillus Calmette-GuerinResection of bladder tumorTreating non-muscle invasive bladder cancerFavorable adverse event profileAdverse event profileBacillus Calmette-GuerinMinor adverse eventsMulti-institutional studyBCG failurePapillary diseaseTransurethral resectionBladder tumorsConsecutive patientsMedian ageMP54-15 A MULTICENTER STUDY OF 2-YEAR OUTCOMES FOLLOWING HYPERTHERMIA THERAPY WITH MITOMYCIN C IN TREATING BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: RECIRCULANT HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY
Stemberger A, Tan W, Bello A, Alvarez J, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Díaz-Goizueta F, Del Alamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, León-Mata J, Moreno J, Molina F, Semino M, Calleja-Escudero J, Redorta J, Tan W. MP54-15 A MULTICENTER STUDY OF 2-YEAR OUTCOMES FOLLOWING HYPERTHERMIA THERAPY WITH MITOMYCIN C IN TREATING BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: RECIRCULANT HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY. Journal Of Urology 2022, 207: e932. DOI: 10.1097/ju.0000000000002633.15.Peer-Reviewed Original Research
2021
Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers In Surgery 2021, 8: 775527. PMID: 34888347, PMCID: PMC8649716, DOI: 10.3389/fsurg.2021.775527.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerInvasive bladder cancerOncological outcomesSafety profileBladder cancerAdverse eventsMeta-analysisBacillus Calmette-Guerin instillationsHigh-risk NMIBC patientsIntravesical bacillus Calmette-GuerinMeta-analysis of clinical studiesBCG maintenance therapySystematic reviewMonths recurrence rateCochrane RoB toolCertainty of evidenceRisk of biasComprehensive literature searchBCG shortageChemotherapy maintenanceNMIBC patientsBCG treatmentMaintenance therapyRecurrence rate1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rateP0773 Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. P0773 Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis. European Urology 2021, 79: s1068-s1069. DOI: 10.1016/s0302-2838(21)01148-9.Peer-Reviewed Original Research
2019
705 Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Schrag D, Kibel A, Chang S. 705 Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories. European Urology Open Science 2019, 18: e942. DOI: 10.1016/s1569-9056(19)30685-2.Peer-Reviewed Original ResearchCost of surveillanceEconomic analysisRisk categoriesNon-muscle invasive bladder cancerInvasive bladder cancer
2018
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong Y, Joshi K, Khetrapal P, Ismail M, Reading J, Sunderland M, Georgiou A, Furness A, Aissa A, Ghorani E, Oakes T, Uddin I, Tan W, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs T, Kelly J, Powles T, Peggs K, Chain B, Linch M, Quezada S. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal Of Experimental Medicine 2018, 215: 2748-2759. PMID: 30257862, PMCID: PMC6219732, DOI: 10.1084/jem.20181003.Peer-Reviewed Original ResearchConceptsMuscle invasive bladder cancerImmune tumor microenvironmentTumor microenvironmentImmuno-oncologyT cellsBladder cancerExpression of PD-1Response to checkpoint blockadeShorter recurrence-free survivalT cell receptor repertoireSource of T cellsEffector CD8<sup>+</sup>Recurrence-free survivalInvasive bladder cancerRegulatory T cellsTumor immune microenvironmentCD4<sup>+</sup> cellsFraction of patientsImmunotherapy combinationsCheckpoint blockadePD-1Cancer immunotherapyCD8<sup>+</sup>Immune microenvironmentPrognostic valueUrinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet?
Tan W, Tan W. Urinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet? Translational Andrology And Urology 2018, 7: s109-s110. PMID: 29644175, PMCID: PMC5881187, DOI: 10.21037/tau.2017.12.18.Peer-Reviewed Original Research
2017
DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells
Tan W, Feber A, Dong L, Sarpong R, Rezaee S, Rodney S, Khetrapal P, de Winter P, Ocampo F, Jalil R, Williams N, Brew-Graves C, Kelly J. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells. BMC Cancer 2017, 17: 767. PMID: 29141603, PMCID: PMC5688623, DOI: 10.1186/s12885-017-3758-7.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerNon-muscle invasive bladder cancer patientsBladder cancerSurveillance cystoscopyUrinary testsRisk of urinary tract infectionPresence of bladder cancerHigh grade bladder cancerDetection of bladder cancerProspective multicentre observational studyRecurrent bladder cancerUpper tract imagingInvasive bladder cancerUrinary sediment cellsUrinary tract infectionNegative predictive valueMulticentre observational studyGrade bladder cancerBladder cancer surveillanceCystoscopy findingsTract infectionsUrine sample collectionHistopathological resultsCystoscopyInvasive proceduresMale Robot-Assisted Radical Cystectomy
Tan W, Sridhar A, Kelly J. Male Robot-Assisted Radical Cystectomy. 2017, 195-205. DOI: 10.1007/978-3-319-65864-3_16.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerMuscle invasive bladder cancerInvasive bladder cancerRadical cystectomyBladder cancerCohort of patientsMinimally invasive cystectomyExposure to environmental carcinogensPerioperative complicationsRecommended treatmentCystectomyCystectomy operationsTobacco smokeEnvironmental carcinogens665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial
Tan W, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths L, Page T, Hodgson D, Datta S, Bilingham L, Kelly J. 665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial. European Urology Open Science 2017, 16: e1156-e1157. DOI: 10.1016/s1569-9056(17)30720-0.Peer-Reviewed Original Research